Perrigo (NYSE:PRGO – Get Free Report) is expected to post its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $0.31 per share and revenue of $1.0134 billion for the quarter. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Investors are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:30 AM ET.
Perrigo (NYSE:PRGO – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. The firm had revenue of $841.80 million for the quarter, compared to analyst estimates of $1.04 billion. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.Perrigo’s revenue for the quarter was down 7.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.60 EPS. On average, analysts expect Perrigo to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Perrigo Stock Up 5.5%
NYSE PRGO opened at $10.66 on Tuesday. The company has a quick ratio of 1.59, a current ratio of 2.72 and a debt-to-equity ratio of 1.45. Perrigo has a fifty-two week low of $9.23 and a fifty-two week high of $27.16. The business has a 50 day moving average price of $10.52 and a two-hundred day moving average price of $11.59. The stock has a market cap of $1.48 billion, a PE ratio of -0.81, a P/E/G ratio of 1.21 and a beta of 0.51.
Perrigo Announces Dividend
Institutional Trading of Perrigo
Hedge funds and other institutional investors have recently made changes to their positions in the business. Geneos Wealth Management Inc. raised its position in Perrigo by 439.1% during the first quarter. Geneos Wealth Management Inc. now owns 965 shares of the company’s stock valued at $27,000 after buying an additional 786 shares during the period. Kestra Investment Management LLC boosted its stake in shares of Perrigo by 57.1% during the 2nd quarter. Kestra Investment Management LLC now owns 1,766 shares of the company’s stock worth $47,000 after acquiring an additional 642 shares in the last quarter. UMB Bank n.a. boosted its stake in shares of Perrigo by 161.5% during the 4th quarter. UMB Bank n.a. now owns 1,964 shares of the company’s stock worth $27,000 after acquiring an additional 1,213 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Perrigo during the 4th quarter valued at about $28,000. Finally, Danske Bank A S bought a new position in shares of Perrigo in the 3rd quarter valued at approximately $53,000. 95.91% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
PRGO has been the subject of several analyst reports. Weiss Ratings upgraded shares of Perrigo from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Zacks Research raised shares of Perrigo from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. One research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Perrigo presently has a consensus rating of “Hold” and a consensus target price of $19.33.
Check Out Our Latest Report on Perrigo
About Perrigo
Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.
Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.
Read More
- Five stocks we like better than Perrigo
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.
